Findings from the VA’s Diuretic Comparison Project show pragmatic trial designs can achieve strong provider participation when burden is minimized and patient care remains the primary focus.

Disc Medicine stock is hit by an FDA CRL for bitopertin. Learn key trial risks, cash runway, and why APOLLO Phase 3 results ...

Diakonos Oncology Corp., a clinical-stage biotechnology company developing a new generation of immunotherapies to treat ...

Good morning, everyone, and thank you for joining us today. Earlier this morning, we issued a press release outlining the positive topline results from our SOL-1 Phase III clinical trial of AXPAXLI, ...

This study provides a useful contribution to understanding how wearable augmentation devices interact with human proprioception, using a longitudinal design over a single session. Results demonstrate ...

Q VYJUVEK revenue and $730.3 million since U.S. launchFDA granted RMAT to KB707 for the treatment of advanced NSCLC and Fast ...

-Remain On Track to Initiate CYC-126's Phase 2 Proof-of-Concept ("POC”) Study in Treatment Resistant Depression ("TRD”) in ...

IDEAYA Biosciences, Inc. , a leading precision medicine oncology company, provided a business update and announced financial results for the fourth quarter and full year ended December 31, ...

PFS events confirmed by BICR in the Phase 2/3 OptimUM-02 trial of darovasertib and crizotinib combination in 1L HLA*A2-negative metastatic uveal melanoma ...

NEW YORK, Feb. 17, 2026 /PRNewswire/ -- The American Journal of Audiology has peer-reviewed and published the positive outcomes of U.S. tinnitus patients treated with Lenire, the only FDA approved ...

BREAKWATER trial Cohort 3 analysis demonstrated statistically significant and clinically meaningful improvement in ...

Sanofi and Teva's duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn's disease In the RELIEVE UCCD LTE phase 2b study, duvakitug ...